McDermott Will & Emery Advises Innate Pharma on New Capital Increase - McDermott Will & Emery

McDermott Will & Emery Advises Innate Pharma on New Capital Increase

Overview


McDermott Will & Emery has advised biotechnology company Innate Pharma on an agreement with the Institute for Follicular Lymphoma Innovation (IFLI) to explore the clinical potential of IPH6501, Innate’s anti-CD20 ANKET® in follicular lymphoma, under which IFLI has invested USD 3 million in new Innate Pharma shares.

The IFLI may also invest up to USD 4.9 million in new shares of Innate Pharma, subject to certain milestones being met, at a price to be determined at the time of such investments.

The McDermott team involved in this transaction was composed of Anne-France Moreau and Emmanuelle Trombe.

About McDermott


McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.